



**New Trogarzo® Data Presented at Conference on Retroviruses and Opportunistic Infections
Demonstrates Sustained Viral Suppression at Week 96**

March 8, 2019

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that new data, presented today at the 26th annual Conference on Retroviruses and Opportunistic Infections (CROI), show that Trogarzo® (ibalizumab-uiyk) injection maintains viral suppression at week 96.